8-K: Alkermes Reports Q1 2026 Results, Updates 2026 Outlook

Alkermes plc announced its first quarter 2026 financial results, reporting total revenues of $392.9 million and updating its full-year financial expectations following the acquisition of Avadel Pharmaceuticals.

Summary

• Alkermes plc reported first quarter 2026 financial results, with total revenues of $392.9 million, an increase from $306.5 million in the first quarter of 2025.
• The company experienced a GAAP net loss of $66.5 million for the quarter, compared to a net income of $22.5 million in Q1 2025.
• Adjusted EBITDA for Q1 2026 was $80.3 million, up from $45.6 million in Q1 2025.
• The acquisition of Avadel Pharmaceuticals was completed in February 2026, contributing to the financial results and updated full-year expectations.
• The Phase 3 Brilliance clinical program for alixorexton in narcolepsy was initiated in Q1 2026.
• Full-year 2026 revenue expectations remain between $1,730 million and $1,840 million, but GAAP net loss is now projected to be between ($70) million and ($90) million, an improvement from the previous forecast.
• Full-year 2026 EBITDA is now expected to be between $105 million and $135 million, an increase from the previous forecast.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed-to-positive filing; while the current quarter shows a net loss, the strategic acquisition and improved full-year outlook, particularly in EBITDA, are positive indicators.

Positives

• Total revenues increased by 28.2% to $392.9 million in Q1 2026 compared to $306.5 million in Q1 2025.
• Proprietary net sales grew significantly to $338.1 million in Q1 2026 from $244.5 million in Q1 2025.
• LYBALVI revenues increased by 32% to $92.4 million.
• ARISTADAi revenues increased by 27.7% to $93.8 million.
• VIVITROL revenues increased by 10.5% to $112.4 million.
• Adjusted EBITDA increased by 76.1% to $80.3 million in Q1 2026 from $45.6 million in Q1 2025.
• Updated full-year 2026 GAAP net loss expectation improved to ($70) million - ($90) million from ($115) million - ($135) million.
• Updated full-year 2026 EBITDA expectation improved to $105 million - $135 million from $60 million - $90 million.

Negatives

• The company reported a GAAP net loss of $66.5 million in Q1 2026, compared to a net income of $22.5 million in Q1 2025.
• EBITDA was a loss of $30.1 million in Q1 2026, compared to a positive $22.8 million in Q1 2025.
• Cash, cash equivalents, and total investments decreased to $538.2 million at March 31, 2026, from $1.32 billion at December 31, 2025, largely due to financing the Avadel acquisition.
• Total expenses increased to $441.2 million in Q1 2026 from $292.7 million in Q1 2025, driven by acquisition-related costs and R&D.

Risks

• The integration of Avadel Pharmaceuticals may not be effective, and expected benefits and value may not be achieved.
• There may be unknown or inestimable liabilities and potential litigation associated with the acquisition.
• Clinical development activities for alixorexton may not be completed on time or at all, or results may not be positive.
• The company faces risks related to the potential therapeutic and commercial value of alixorexton and other development candidates.
• Potential changes in the cost, scope, and duration of development programs could impact financial performance.
• Adverse decisions from regulatory authorities like the FDA regarding products or product candidates are a risk.
• Third parties may have proprietary rights that preclude commercialization of Alkermes' products.
• The company is subject to risks described in its Form 10-K for the year ended December 31, 2025, and subsequent filings.

Future Outlook

The company updated its full-year 2026 financial expectations, maintaining total revenue guidance between $1,730 million and $1,840 million. However, the GAAP net loss is now projected to be between ($70) million and ($90) million, an improvement from the previous forecast of ($115) million to ($135) million. EBITDA is now expected to be between $105 million and $135 million, up from the previous $60 million to $90 million range. Adjusted EBITDA expectations remain unchanged at $370 million to $410 million.

Management Comments

• "We delivered a strong quarter marked by solid financial and commercial execution, alongside meaningful strategic progress that positions Alkermes as an emerging leader in sleep medicine," said Richard Pops, Chairman and Chief Executive Officer of Alkermes.
• "During the quarter, we successfully closed the acquisition of Avadel, strengthening our financial profile and accelerating our entry into the commercial sleep medicine market at scale."
• "We are also rapidly advancing the alixorexton development program and recently initiated the phase 3 Brilliance studies to further characterize alixorextons differentiated profile and potential utility in both narcolepsy type 1 and type 2."
• "The multibilliondollar market opportunity in narcolepsy and idiopathic hypersomnia represents a transformative opportunity for Alkermes."
• "Taken together with the broad therapeutic potential across other neuropsychiatric disorders, orexin 2 receptor agonists represent one of the most exciting new therapeutic categories in neuroscience, and Alkermes is at the forefront of generating new clinical data and expanding our understanding of this neurocircuitry."

Industry Context

StockSavvy.ai notes that Alkermes' strategic focus on neuroscience, particularly with the acquisition of Avadel and the advancement of alixorexton for narcolepsy, aligns with a growing industry interest in novel treatments for sleep disorders and other central nervous system conditions. The company is positioning itself to capitalize on the expanding market for treatments addressing unmet needs in neuropsychiatry.

Legal Proceedings

• The filing mentions potential litigation associated with the acquisition of Avadel Pharmaceuticals as a risk factor.

Stakeholder Impact

• Shareholders: The improved full-year EBITDA outlook and reduced net loss forecast may be viewed positively, but the current quarter's net loss and the significant debt financing for the acquisition could be concerns.
• Creditors: The company has taken on $1.525 billion in term loans, impacting its debt profile.
• Employees: The acquisition of Avadel may lead to integration efforts and potential changes within the combined organization.
• Suppliers/Customers: Continued commercialization of existing products and the integration of Avadel's operations will impact these stakeholders.

Next Steps

• Continue advancing the alixorexton development program, including Phase 3 Brilliance studies.
• Integrate the acquired Avadel Pharmaceuticals business.
• Continue commercial execution for VIVITROL, ARISTADAi, LYBALVI, and LUMRYZ.
• Monitor and manage the financial performance against updated 2026 expectations.

Key Dates

Recommendation

The company has made significant strategic moves with the Avadel acquisition, which is expected to bolster its position in the sleep medicine market. While the current quarter's results show a net loss, the improved full-year guidance for EBITDA and reduced net loss forecast are encouraging. However, the substantial debt taken on for the acquisition and the inherent risks in clinical development warrant a cautious 'hold' rating until the integration benefits and pipeline progress become clearer.

Keywords

Alkermes, SEC Filing, 8-K, Financial Results, Q1 2026, Avadel Pharmaceuticals, Narcolepsy, Alixorexton